Aerovate Therapeutics, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Aerovate Therapeutics, Inc. has filed its 2023 annual report (10-K) detailing financial data and business operations.</b>

AI Summary

Aerovate Therapeutics, Inc. (JBIO) filed a Annual Report (10-K) with the SEC on March 25, 2024. Aerovate Therapeutics, Inc. filed its 2023 Form 10-K on March 25, 2024. The company is incorporated in Delaware and its fiscal year ends on December 31. Its principal business address is located at 930 Winter Street, Suite M-500, Waltham, MA 02451. The filing includes data related to common stock, retained earnings, and additional paid-in capital for 2023, 2022, and 2021. Fair value measurements for various debt securities (US Government Agencies, Corporate Debt, Commercial Paper, US Treasury Securities) are detailed for 2023 and 2022.

Why It Matters

For investors and stakeholders tracking Aerovate Therapeutics, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Aerovate Therapeutics' financial health and operational status for the fiscal year ending December 31, 2023, which is crucial for investors to assess the company's performance and future prospects. The detailed breakdown of financial instruments and equity components offers insights into the company's capital structure and investment strategies, important for understanding its risk profile and valuation.

Risk Assessment

Risk Level: medium — Aerovate Therapeutics, Inc. shows moderate risk based on this filing. The company's financial disclosures, particularly regarding fair value measurements of debt securities and equity components, suggest a need for careful investor scrutiny, though specific operational or market risks are not detailed in this header information.

Analyst Insight

Investors should review the full 10-K filing to understand Aerovate Therapeutics' financial performance, strategic initiatives, and risk factors for the fiscal year 2023.

Key Numbers

• 2023-12-31 — Fiscal Year End (Period of report)
• 2024-03-25 — Filing Date (Date filed)
• 2834 — SIC Code (Standard Industrial Classification)
• 001-40544 — SEC File Number (SEC filing details)

Key Players & Entities

• Aerovate Therapeutics, Inc. (company) — Filer name
• Waltham, MA (location) — Business address city and state
• 2023-12-31 (date) — Fiscal year end
• 2024-03-25 (date) — Filing date
• PHARMACEUTICAL PREPARATIONS (industry) — Standard Industrial Classification
• DE (location) — State of incorporation

FAQ

Industry Context

Aerovate Therapeutics operates within the Pharmaceutical Preparations industry (SIC 2834).

Regulatory Implications

As a public company, Aerovate Therapeutics is subject to the reporting requirements of the Securities Exchange Act of 1934, including the filing of annual reports on Form 10-K.

What Investors Should Do

1. Review the full Form 10-K for detailed financial statements and management discussion.
2. Analyze the company's business strategy and pipeline as outlined in the filing.
3. Assess the risk factors section for potential challenges and uncertainties.

Key Dates

• 2023-12-31: Fiscal Year End — Defines the reporting period for the 10-K.
• 2024-03-25: Filing Date — Indicates when the 10-K was officially submitted to the SEC.

Year-Over-Year Comparison

This is the initial 10-K filing for Aerovate Therapeutics, Inc. as indicated by the filing date and the absence of prior period comparative data in the provided header.

Key Financial Figures

• $0.0001 — ch registered Common stock, par value $0.0001 per share AVTE The Nasdaq Global Ma
• $17.15 — reported on the Nasdaq Global Market of $17.15 per share. In determining the market va
• $6.2 billion — obal sales for PAH products in 2023 was $6.2 billion. Despite the availability of multiple a
• $1 billion — e's acquisition of GelTex for more than $1 billion. Benjamin T. Dake, Ph.D., our Founder,

Filing Documents

• tmb-20231231x10k.htm (10-K) — 2308KB
• tmb-20231231xex10d9.htm (EX-10.9) — 87KB
• tmb-20231231xex19d1.htm (EX-19.1) — 57KB
• tmb-20231231xex21d1.htm (EX-21.1) — 4KB
• tmb-20231231xex23d1.htm (EX-23.1) — 2KB
• tmb-20231231xex31d1.htm (EX-31.1) — 11KB
• tmb-20231231xex31d2.htm (EX-31.2) — 11KB
• tmb-20231231xex32d1.htm (EX-32.1) — 6KB
• tmb-20231231xex32d2.htm (EX-32.2) — 6KB
• tmb-20231231x10k001.jpg (GRAPHIC) — 42KB
• tmb-20231231x10k002.jpg (GRAPHIC) — 38KB
• tmb-20231231x10k003.jpg (GRAPHIC) — 38KB
• tmb-20231231x10k004.jpg (GRAPHIC) — 50KB
• tmb-20231231x10k005.jpg (GRAPHIC) — 94KB
• tmb-20231231x10k006.jpg (GRAPHIC) — 61KB
• tmb-20231231x10k007.jpg (GRAPHIC) — 24KB
• tmb-20231231x10k008.jpg (GRAPHIC) — 51KB
• tmb-20231231x10k009.jpg (GRAPHIC) — 45KB
• tmb-20231231x10k010.jpg (GRAPHIC) — 73KB
• tmb-20231231x10k011.jpg (GRAPHIC) — 33KB
• 0001798749-24-000015.txt (&nbsp;) — 9881KB
• tmb-20231231.xsd (EX-101.SCH) — 38KB
• tmb-20231231_cal.xml (EX-101.CAL) — 57KB
• tmb-20231231_def.xml (EX-101.DEF) — 143KB
• tmb-20231231_lab.xml (EX-101.LAB) — 382KB
• tmb-20231231_pre.xml (EX-101.PRE) — 302KB
• tmb-20231231x10k_htm.xml (XML) — 1534KB

Business

Business 7 Item 1A.

Risk Factors

Risk Factors 49 Item 1B. Unresolved Staff Comments 97 Item 1C. Cybersecurity 97 Item 2.

Properties

Properties 98 Item 3.

Legal Proceedings

Legal Proceedings 98 Item 4. Mine Safety Disclosures 98 PART II 98 Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 98 Item 6. Reserved 99 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 99 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 106 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 107 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 107 Item 9A.

Controls and Procedures

Controls and Procedures 107 Item 9B. Other Information 108 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 108 PART III 109 Item 10. Directors, Executive Officers and Corporate Governance 109 Item 11.

Executive Compensation

Executive Compensation 109 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 109 Item 13. Certain Relationships and Related Transactions, and Director Independence 109 Item 14. Principal Accounting Fees and Services 109 PART IV 109 Item 15. Exhibits, Financial Statement Schedules 109 Item 16. Form 10-K Summary 109

Signatures

Signatures 112 2 Table of Contents SUMMARY OF THE MATERIAL AND OTHER RISKS ASSOCIATED WITH OUR BUSINESS Our business is subject to numerous material and other risks and uncertainties that you should be aware of in evaluating our business. These risks include, but are not limited to, the following: We are a clinical-stage biopharmaceutical company with a limited operating history. We have incurred significant operating losses since our inception and anticipate that we will continue to incur losses for the foreseeable future. We may never achieve or maintain profitability. We have no products approved for commercial sale and have not generated any revenue from product sales. Our business is entirely dependent on the successful development, regulatory approval and commercialization of AV-101, our only product candidate under development. We are conducting our first late-stage clinical trial of AV-101, a dry powder formulation of imatinib for the treatment of PAH administered using a dry powder inhaler, to assess its safety and tolerability. Although we believe that AV-101 has therapeutic potential for PAH based on oral imatinib's results in the Phase 3 IMPRES trial, we are utilizing a novel dry powder formulation which may not achieve better or similar levels of clinical activity or may have similar tolerability challenges as oral imatinib. The results of earlier studies and trials of oral imatinib in PAH patients and our Phase 1 clinical trial of AV-101 in healthy volunteers may not be predictive of future trial results for AV-101. If we encounter future difficulties with site activation and patient enrollment in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected. We face, and will continue to face, significant competition and our failure to effectively compete may prevent us from achieving significant market penetration for AV-101, if approved. Most of our competitors have significantly greater reso

Business

Item 1. Business. Unless the context requires otherwise, references in this Annual Report on Form 10-K to "Aerovate", "we", "us" and "our" refer to Aerovate Therapeutics, Inc. Overview We are a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Our initial focus is on advancing AV-101, our dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, or PAH, a devastating disease impacting approximately 70,000 people in the United States and Europe. Imatinib, marketed as Gleevec tablets, was originally developed for the treatment of multiple cancers. Oral imatinib also demonstrated statistically significant improvement on the primary endpoint, six-minute walk distance, and multiple secondary hemodynamic endpoints in PAH patients in an international Phase 3 trial conducted by Novartis but was poorly tolerated due to adverse events, or AEs, and never approved for the treatment of PAH. AV-101, delivered using a dry powder inhaler, is designed to provide lung concentrations at or above those observed with the oral dose while limiting systemic levels of the drug. We have completed a Phase 1 clinical trial in healthy volunteers and AV-101 was generally well-tolerated with no serious adverse events reported. In November 2023, we completed enrollment in the Phase 2b portion and enrolled the first patient in the Phase 3 portion of Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT), our global Phase 2b/Phase 3 trial of AV-101 in adults with PAH. We have assembled a team with deep expertise in developing innovative PAH and inhaled therapies and commercializing novel drugs. PAH is an orphan disease with unmet medical need and is characterized by high pressure in the vessels transporting blood from the right side of the heart to the lungs. This high pressure is caused by abnormal cellular hyperproliferation and resist

View Full Filing

View this 10-K filing on SEC EDGAR